Stockscreener 앱 받기
5.6001
2.87%
0.0201
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women - PR Newswire
Atossa Genetics stock surges after FDA rare disease designation By Investing.com - Investing.com South Africa
Atossa Genetics stock surges after FDA rare disease designation - Investing.com
Atossa Therapeutics (ATOS) Secures FDA Designation for Pediatric Treatment - GuruFocus
Atossa gets rare pediatric disease tag for endoxifen in MAS By Investing.com - Investing.com South Africa
FDA awards Atossa Therapeutics rare pediatric designation for Z-endoxifen milestone - Traders Union
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome - PR Newswire
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - Aktiellt
Atossa Therapeutics joins industry leaders at LSINW2026 to advance cell therapy innovation momentum - Traders Union
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights - TipRanks
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com - Investing.com South Africa
Atossa Therapeutics reaches settlement in Endoxifen patent dispute - Investing.com
Atossa Therapeutics (NASDAQ: ATOS) settles key Endoxifen patent fight - Stock Titan
Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62 - MSN
Atossa Therapeutics advances endoxifen as new option for DMD management - Traders Union
ATOS: Ascendiant Capital Lowers Price Target Despite Maintaining 'Buy' Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026 - Traders Union
Atossa Therapeutics: A 2026 Regulatory Milestone in Sight - AD HOC NEWS
ATOS Stock Eyes Fresh Highs Amid Strong Buying Pressure - Cổng thông tin điện tử Tỉnh Sơn La
Atossa Therapeutics Seeks Shareholder Approval for Further Stock Consolidation - AD HOC NEWS
Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split - Stock Titan
Atossa Therapeutics announces issuance of U.S. patent - MSN
Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years - Stock Titan
[ARS] ATOSSA THERAPEUTICS, INC. SEC Filing - Stock Titan
[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement - Stock Titan
NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation - Traders Union
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Entry Recap: Is Atossa Therapeutics Inc a speculative investment2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Risk Off: Is Atossa Therapeutics Inc stock heavily shorted2026 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
ATOS Price Today: Atossa Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
H.C. Wainwright raises Atossa Genetics price target to $25 from $7 - Investing.com
ATOS Receives Significant Price Target Increase from HC Wainwrig - GuruFocus
Atossa Therapeutics (ATOS) Sees Increased Price Target Following Stock Split - GuruFocus
Aug Weekly: Is Atossa Therapeutics Incs growth already priced in2026 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology - Minichart
Atossa Therapeutics 2025 Annual Report: (Z)-Endoxifen Clinical Development, Intellectual Property, and Regulatory Strategy - Minichart
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss - GuruFocus
Atossa Genetics Investors to Decide on Key Corporate Proposals - AD HOC NEWS
0.78%
3.01%
자본화:
|
볼륨(24시간):